AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
September 03 2020 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer of AVEO, will
participate in two upcoming virtual investor conferences:
Baird 2020 Global Healthcare Conference Date: Thursday,
September 10 Time: 8:30 AM Eastern Time
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14 Time: 4:30 PM Eastern Time
A live webcast of the events can be accessed by visiting the
investors section of the Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is developing an oncology pipeline designed to provide a
better life for patients with cancer. AVEO’s strategy is to focus
its resources toward development and commercialization of its
product candidates in North America, while leveraging partnerships
to support development and commercialization in other geographies.
AVEO’s lead candidate, tivozanib (FOTIVDA®) is approved in the
European Union and other countries by AVEO’s partner EUSA for the
treatment of adult patients with advanced renal cell carcinoma.
AVEO is working to develop and commercialize tivozanib in North
America as a treatment for renal cell carcinoma and hepatocellular
carcinoma. AVEO has previously reported promising early clinical
data on ficlatuzumab (anti-HGF mAb) in head and neck cancer, acute
myeloid leukemia and pancreatic cancer and is conducting a
randomized Phase 2 confirmatory clinical trial of ficlatuzumab in
head and neck cancer. AVEO’s earlier-stage pipeline includes
several monoclonal antibodies in oncology development, including
AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353
(anti-Notch 3 mAb). AVEO is committed to creating an environment of
diversity and inclusion as a foundation for innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005012/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024